- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C. , June 12, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical
DURHAM, N.C. , June 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation for brincidofovir for the treatment
DURHAM, N.C. , June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey , MD, MPH will deliver remarks before the House Committee on
- Landmark AdVance Study Demonstrates Strong Correlation Between Adenovirus Burden and Mortality Risk - - Site Initiations for AdAPT Study of Oral Short-course Brincidofovir for Adenovirus and IV Brincidofovir Programs Are Progressing – - First Presentation on CMX521 for Norovirus in June- -
DURHAM, N.C. , May 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
DURHAM, N.C. , April 30, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m.
DURHAM, N.C. , April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols , M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C.
DURHAM, N.C. , March 29, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the appointment of Martha J. Demski as Chair of the Board of Directors. Martha will succeed Ernest Mario , PhD, who is
European, multi-center study reinforces need for effective therapies for adenovirus in immunocompromised patients DURHAM, N.C. , March 19, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data
DURHAM, N.C. , March 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
